Physicists rediscover a discarded theory to solve a mystery of how glass damping sound phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.
Share:
FOSTER CITY, Calif. and BAD HOMBURG, Germany, Dec. 10, 2020 /PRNewswire/ Gilead Sciences, Inc. (NASDAQ:GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million (both payments subject to customary adjustments).
The acquisition will provide Gilead with Hepcludex
™ (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. MYR has since launched Hepcludex in France, Germany and Austria, and continues to prepare for launch in certain other markets throughout 2021. It is e
Gilead Sciences, Inc.: Gilead Sciences to Acquire MYR GmbH Gilead to Acquire Hepcludex
, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction
- Hepcludex Was Conditionally Approved in Europe in July 2020 Based on Phase 2 Data and Submission for Accelerated Approval in United States is Anticipated in Second Half of 2021
Acquisition Builds on Gilead s Strength as a Global Leader in Virology and Liver Diseases with Addition of First Marketed Product for Treatment of HDV
Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential fut